10-Q: Adtalem Q1 FY26 Revenue Jumps 10.8% Amid Regulatory Shifts

Adtalem Global Education reported a strong first quarter for fiscal year 2026 with revenue up 10.8% and diluted EPS increasing 41.5%, despite ongoing regulatory changes and uncertainties from the new One Big Beautiful Bill Act.

Summary

• Revenue increased 10.8% to $462.3 million in the first quarter of fiscal year 2026, up from $417.4 million in the prior year period.
• Net income rose 33.9% to $61.8 million, compared to $46.2 million in the prior year period.
• Diluted earnings per share (EPS) increased 41.5% to $1.67, up from $1.18 in the prior year period.
• Adjusted net income grew 28.5% to $64.9 million, and diluted adjusted EPS increased 35.7% to $1.75.
• Operating income (GAAP) increased 21.7% to $85.5 million, while adjusted operating income (non-GAAP) increased 19.0% to $90.3 million.
• Interest expense decreased to $11.1 million from $14.5 million in the prior year, driven by lower borrowings and interest rates on the Term Loan B.
• Restructuring expense significantly decreased to $0.3 million from $2.1 million in the prior year period.
• Student enrollment increased across all segments: Chamberlain (July 2025 +4.5%, Sept 2025 +2.2%), Walden (Sept 30, 2025 +13.6%), and Medical and Veterinary schools (Sept 2025 +2.4%).
• The One Big Beautiful Bill Act (OBBBA) was signed into law in July 2025, introducing substantial changes to federal student aid, including increased unsubsidized loan limits for professional programs, phasing out the Grad PLUS loan program, new aggregate federal loan caps, and 'Do No Harm' provisions.
• The 2022 Borrower Defense to Repayment (BDR) regulations were delayed until July 1, 2035, with the 2019 regulations restored, following litigation and the enactment of OBBBA.
• The company received 14,934 BDR claims across its institutions, to which it has responded, believing none properly state an eligible claim for loan forgiveness.
• Adtalem repurchased 56,817 shares of common stock at an average cost of $133.66 per share during the quarter, with $142.4 million remaining under the current share repurchase program.

Sentiment

Score: 7

Explanation: Adtalem delivered strong financial results with significant revenue and EPS growth, and positive enrollment trends across all segments. However, substantial regulatory changes from the One Big Beautiful Bill Act (OBBBA) and ongoing uncertainties surrounding Gainful Employment rules and Borrower Defense to Repayment claims introduce considerable future risk and complexity to the operating environment.

Positives

• Revenue increased by 10.8% to $462.3 million, driven by growth across all segments.
• Net income increased by 33.9% to $61.8 million, and diluted EPS grew by 41.5% to $1.67.
• Adjusted net income and diluted adjusted EPS also saw significant increases of 28.5% and 35.7%, respectively.
• Interest expense decreased by $3.4 million due to lower borrowings and a reduced interest rate on the Term Loan B.
• Restructuring expense decreased substantially from $2.1 million to $0.3 million.
• All educational segments experienced enrollment growth: Chamberlain (+4.5% and +2.2%), Walden (+13.6%), and Medical and Veterinary schools (+2.4%).
• The company increased its revolving credit facility by $100.0 million to $500.0 million and extended its maturity to August 6, 2030, enhancing liquidity.
• The One Big Beautiful Bill Act (OBBBA) may have positive effects by applying the same rules to all Title IV institutions, creating a level playing field for proprietary higher education.

Negatives

• Chamberlain's adjusted operating income decreased by 8.0% to $25.6 million, primarily due to increased labor, marketing, and growth initiative costs.
• The One Big Beautiful Bill Act (OBBBA) introduces significant uncertainty regarding federal student aid availability, including the phasing out of the Grad PLUS loan program and new aggregate loan caps, which could materially adversely affect the business.
• The company's fiscal year 2022 composite financial responsibility score declined to 0.2, resulting in provisional certifications for its institutions, heightened cash monitoring, and a requirement to maintain $179.0 million in letters of credit.
• New Financial Value Transparency (FVT) and Gainful Employment (GE) rules, effective July 1, 2024, could lead to programs losing Title IV eligibility if they fail debt-to-earnings or earnings premium tests.
• The 90/10 Rule was amended to include all federal education assistance funds, potentially increasing compliance challenges for proprietary institutions.

Risks

• The One Big Beautiful Bill Act (OBBBA) introduces substantial changes to federal student aid, including increased loan limits for professional programs, phasing out the Grad PLUS loan program, new aggregate federal loan caps for new students starting July 1, 2026, and reduced loan amounts for part-time students, which could materially adversely affect the business.
• The 'Do No Harm' provisions of OBBBA could lead to programs losing Title IV eligibility if completers' earnings do not exceed those of a high school diploma (undergrad) or bachelor's degree (grad/professional) population for two years in a a three-year period, with implementing regulations yet to be promulgated.
• New Financial Value Transparency (FVT) and Gainful Employment (GE) rules, effective July 1, 2024, require programs to meet debt-to-earnings and earnings premium tests; failure could result in warnings or loss of Title IV eligibility.
• The company's composite financial responsibility score of 0.2 requires provisional certifications for its institutions, heightened cash monitoring, and maintaining significant letters of credit, which could lead to closer scrutiny by the Department of Education (ED).
• The amended 90/10 Rule, effective for fiscal year 2024, now includes all federal education assistance funds, increasing the risk of non-compliance and potential loss of Title IV eligibility if the 90% threshold is exceeded for two consecutive fiscal years.
• Borrower Defense to Repayment (BDR) claims, although currently under the 2019 regulations, still pose a financial liability and reputational risk, with a significant number of claims received by Adtalem's institutions.
• Ongoing litigation and settlements related to divestitures, such as the sale of DeVry University, continue to incur costs and could require significant resources.
• Economic conditions deteriorating or operating performance not meeting expectations could lead to impairments of goodwill and other intangible assets in future periods.

Future Outlook

The company anticipates that the One Big Beautiful Bill Act (OBBBA) will significantly reshape the federal student aid landscape, with the full impact yet to be determined pending implementing regulations. Management is actively engaging with other financing sources to provide loan programs for students to replace funding limited by OBBBA. Capital expenditures for fiscal year 2026 are expected to include information technology investments and new campus development at Chamberlain. The company believes its cash flows from operations, existing cash balances, and credit facility availability will provide sufficient liquidity for current obligations, working capital, capital spending, and anticipated stock repurchases for the next several years.

Management Comments

• Management's focus for the Medical and Veterinary segment is on increasing enrollment and renewing operational effectiveness, specifically around academic support and the enrollment experience.
• We believe our cash flows from operations, and our existing cash balances, combined with availability under our credit facility and access to the debt markets, will provide sufficient liquidity to fund our current obligations, projected working capital requirements, capital spending, and anticipated stock repurchases for a period that includes the next twelve months as well as the next several years.

Industry Context

The postsecondary education industry, particularly for proprietary institutions like Adtalem, is undergoing significant regulatory transformation. The newly enacted One Big Beautiful Bill Act (OBBBA) and the updated Financial Value Transparency (FVT) and Gainful Employment (GE) rules represent a major shift in federal oversight of student aid and program outcomes. These changes aim to level the playing field across all Title IV participating institutions but introduce considerable uncertainty regarding student financing and program eligibility. Adtalem's proactive engagement with alternative financing sources reflects an industry-wide need to adapt to reduced federal loan availability. The ongoing Borrower Defense to Repayment (BDR) claims and the amended 90/10 Rule further highlight the heightened regulatory scrutiny and compliance burden faced by institutions in this sector.

Comparison to Industry Standards

• NA

Legal Proceedings

• Adtalem is subject to lawsuits, administrative proceedings, regulatory reviews, and investigations associated with financial assistance programs and other matters.
• The company continues to incur costs associated with ongoing litigation and settlements related to divestitures, including the sale of DeVry University.
• Adtalem's institutions have received 14,934 Borrower Defense to Repayment (BDR) claims, to which they have responded, believing none properly stated an eligible claim for loan forgiveness. No approvals or recoupment intent notices have been received from ED to date.

Stakeholder Impact

• Shareholders: Positive financial performance and ongoing share repurchase program could enhance shareholder value, but significant regulatory uncertainties pose potential risks to future earnings and stock price.
• Students: Will be directly impacted by changes to federal student aid programs under OBBBA, including new loan limits and the phasing out of Grad PLUS loans, potentially requiring reliance on new financing sources.
• Employees: Prior restructuring involved workforce reductions, but current period shows reduced restructuring expense, suggesting a more stable employment outlook.
• Regulatory Bodies: Adtalem remains under close scrutiny by the U.S. Department of Education (ED) due to its financial responsibility composite score, provisional PPAs, and compliance with evolving rules like OBBBA, GE, and 90/10.

Next Steps

• The U.S. Department of Education (ED) will commence negotiated rulemaking regarding the education-related provisions of OBBBA, with committees addressing FVT/GE scheduled to meet in December 2025 and January 2026.
• Adtalem is in discussions with other financing sources to provide loan programs for students to replace funding that will be limited by OBBBA.
• The company plans future capital expenditures for information technology investments and new campus development at Chamberlain.
• Adtalem intends to continue its share repurchase program, with $142.4 million remaining under the current authorization.

Key Dates

Recommendation

While Adtalem delivered strong financial results with significant revenue and EPS growth, the substantial regulatory changes introduced by the One Big Beautiful Bill Act (OBBBA) and the ongoing uncertainty surrounding Gainful Employment rules and Borrower Defense to Repayment claims create a complex and potentially volatile operating environment. The long-term impact of these regulations on student enrollment, financial aid eligibility, and ultimately, profitability, is not yet fully quantifiable. The company's proactive measures, such as increasing its revolving credit facility and seeking alternative financing sources for students, are positive, but the regulatory landscape warrants a cautious approach. Investors should hold to monitor how these regulatory uncertainties unfold and the company's ability to adapt.

Keywords

Adtalem, ATGE, Education, Healthcare Education, Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, Ross University School of Veterinary Medicine, SEC Filing, 10-Q, Financial Results, Student Enrollment, Title IV, OBBBA, Gainful Employment, 90/10 Rule, Borrower Defense to Repayment, Higher Education Act, Financial Aid, Quarterly Report